Clinical Trial Update: Enzalutamide and External Beam Hypofractionated Radiotherapy For Intermediate Risk Localized Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating enzalutamide with external beam hypofractionated radiotherapy for intermediate-risk localized prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Carcinoma

Drugs mentioned

• Enzalutamide (enzalutamide)

Snippet

Sponsor: Fundación Canaria de Investigación Sanitaria | Conditions: Prostate Carcinoma | Phase 2 | Status: UNKNOWN